Ask AI

Gastrointestinal Cancers

For coverage of lymphoma and leukemia at ASCO and EHA 2026, click here.

Share

Program Content

Activities

  • RASolute 302
    RASolute 302: Phase III Trial of Daraxonrasib vs Chemotherapy in Previously Treated Metastatic Pancreatic Adenocarcinoma
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 10, 2026

  • FIGHT-302
    FIGHT-302: Phase III Trial of Pemigatinib as First-line Treatment for Unresectable Advanced or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 11, 2026

  • EMERALD-3
    EMERALD-3: Phase III Trial of Tremelimumab + Durvalumab ± Lenvatinib Combined With TACE in Unresectable Embolization-Eligible HCC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 11, 2026

  • HERIZON GEA 01 PDL1 Subgroup Analysis
    HERIZON-GEA-01: PD-L1 Subgroup Analysis From Phase III Trial of Zanidatamab + Chemotherapy ± Tislelizumab for First-line HER2+ Locally Advanced or Metastatic GEA
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 16, 2026

  • HORIZON-CRC01
    HORIZON-CRC01: Phase III Trial of Trastuzumab Rezetecan vs SoC in Chemorefractory, HER2+ Advanced CRC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 16, 2026

Supporters

This activity is supported by an educational grant from Incyte Corporation.

Incyte Corporation